Comment: cost-effective pharmaceutical care for HIV disease.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M E Hoar.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
The Food and Drug Administration contend that there is no evidence to support the notion of serious quality differences between brand name and generic drugs. In contrast, research-intensive pharmaceutical firms believe they produce a product of higher quality than other manufacturers. This paper reviews and critically evaluates the arguments presented by both sides of this issues. Discussed are the 1978 Lilly Report, the 1980 FDA Study, and Block's 1980 Computer Study of FDA Citations.
Because of FDA requirements concerning patient package inserts and growing awareness of the need for patient education, pharmacists and other health care practitioners have become interested in assessing the readability of written information intended for patients. Readability formulas have seemingly furnished a quick and easy answer. However, users of readability formulas should be aware of their limitations. Several of these limitations are presented, along with suggestions for overcoming them. This approach will enable pharmacists and other health care practitioners to become more sophisticated in assessing the readability of various documents and ultimately to produce readable documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.